FDA Centers and Offices: A Complete Breakdown

The U.S. Food and Drug Administration is organized into a network of product-specific centers and cross-cutting offices, each carrying distinct regulatory authority over a defined slice of the U.S. market. Understanding which center governs a particular product — and what authority that center holds — is foundational to navigating approval pathways, enforcement exposure, and compliance obligations. This page maps the full organizational structure, explains how centers and offices interact, and identifies the classification boundaries that determine where a product or submission lands within the FDA hierarchy. For a broader view of the agency's regulatory reach, the FDA Authority resource index provides a structured entry point.

Definition and scope

The FDA operates under the Department of Health and Human Services (HHS) and derives its authority primarily from the Federal Food, Drug, and Cosmetic Act (FD&C Act), codified at 21 U.S.C. § 301 et seq., as well as the Public Health Service Act (42 U.S.C. § 201 et seq.). Within that statutory framework, the agency divides its regulatory work across 5 product-focused centers and a set of agency-wide offices responsible for cross-cutting functions such as criminal investigations, policy coordination, and regulatory science.

The 5 primary product centers are:

  1. Center for Drug Evaluation and Research (CDER) — regulates prescription drugs, over-the-counter drugs, and generic drugs
  2. Center for Biologics Evaluation and Research (CBER) — regulates vaccines, blood products, gene therapies, and certain cellular therapies
  3. Center for Devices and Radiological Health (CDRH) — regulates medical devices and radiation-emitting electronic products
  4. Center for Food Safety and Applied Nutrition (CFSAN) — regulates food, dietary supplements, and cosmetics
  5. Center for Veterinary Medicine (CVM) — regulates animal food and veterinary drug products

A sixth operational unit, the Center for Tobacco Products (CTP), was established following the Family Smoking Prevention and Tobacco Control Act of 2009 (21 U.S.C. § 387 et seq.) and holds authority over tobacco and nicotine products distinct from the other five centers.

The Office of the Commissioner (OC) sits above all centers and coordinates cross-center policy, sets agency-wide priorities, and houses specialized offices including the Office of Combination Products and the Office of Criminal Investigations.

How it works

Each center maintains its own review divisions, scientific staff, and regulatory guidance infrastructure, but all operate under the Commissioner's overarching authority. Product submissions — such as a New Drug Application filed with CDER or a 510(k) clearance request submitted to CDRH — are routed to the appropriate center based on the product's primary mode of action and regulatory classification.

The routing of combination products — those that combine drug, device, and/or biologic components — is handled by the Office of Combination Products (OCP), which sits within the Office of the Commissioner. The OCP issues a Request for Designation (RFD) that legally assigns the product to a lead center (21 C.F.R. Part 3). This determination is binding and drives which approval pathway, labeling requirements, and post-market obligations apply.

The Office of Regulatory Affairs (ORA) functions as the FDA's field operations arm. ORA's roughly 5,000 staff conduct facility inspections, manage import operations, and coordinate enforcement actions across all product centers. ORA does not conduct independent scientific review; it serves as the investigative and compliance infrastructure that feeds findings to the relevant center.

Within CDER, 17 Office of New Drugs review divisions are organized by therapeutic area (e.g., cardiovascular, oncology, anti-infectives). Each division holds authority to issue Complete Response Letters, approve labeling, and recommend enforcement referrals for its product class.

Common scenarios

Drug vs. biologic classification: A monoclonal antibody intended for human therapeutic use is regulated by CBER, not CDER — even though it is administered like a drug. As of March 23, 2020, the FDA transferred oversight of most therapeutic biological products (excluding allergenic products, blood, blood components, and certain other biologics) from CBER to CDER, following a phased transition that began in 2003. Sponsors with products crossing this boundary must confirm the current lead center assignment before submitting a Biologics License Application.

Food additive vs. dietary supplement: A substance added to conventional food falls under CFSAN's food additive and GRAS (Generally Recognized as Safe) framework (21 C.F.R. Part 170). The same substance marketed in a capsule form and labeled for a health benefit may shift into CFSAN's dietary supplement regulatory track under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Both tracks are administered by CFSAN, but with substantially different pre-market requirements.

Digital health and software: CDRH holds jurisdiction over Software as a Medical Device (SaMD). The FDA's Digital Health and Software Regulation framework, including the De Novo and 510(k) pathways applicable to certain software functions, is administered through CDRH's Digital Health Center of Excellence, established in 2020.

Decision boundaries

The boundary between centers is not always self-evident, and misclassification carries material regulatory consequences — including submission to the wrong center, application of the wrong approval standard, and potential enforcement exposure for marketing a product without the required authorization.

Key decision boundaries include:

Boundary Governing Rule Administering Office
Drug vs. biologic (therapeutic protein) 42 U.S.C. § 262 (PHS Act) CDER or CBER based on product type
Drug vs. device (combination product) Primary mode of action test, 21 C.F.R. § 3.7 OCP issues RFD
Food additive vs. GRAS 21 U.S.C. § 321(s); 21 C.F.R. Part 170 CFSAN
Medical device vs. general wellness product FDA Wellness Policy Guidance (FDA.gov) CDRH
Human drug vs. animal drug Species of intended use; 21 U.S.C. § 360b CVM vs. CDER

The FDA organizational structure page details the reporting hierarchy above the center level, including how the Commissioner's office interfaces with HHS and Congress. The FDA mission and authority page situates each center's jurisdiction within the broader statutory mandate.

For regulated industries, identifying the correct center at the earliest stage of product development — ideally before an Investigational New Drug (IND) or Pre-Submission meeting is requested — reduces the risk of jurisdictional disputes and duplicated review timelines.

Read Next

FDA History and Major Milestones The U.S. Food and Drug Administration traces a legislative and institutional arc spanning more than a century, shaped by public... FDA Organizational Structure and Leadership The U.S. Food and Drug Administration operates through a defined hierarchy of offices, centers, and leadership positions that... FDA Budget, Funding Sources, and User Fees The FDA operates through a hybrid funding model that draws on both congressional appropriations and industry-paid user fees — a...